Newsletter

310210 - Voronoi, Inc.

310210 Summary

Biopharma

Stock Price & Overview

₩148,300 -1,400 (-0.94%) Close · Sep 9, 2026 KST

KOSDAQ | ₩KRW | Close: ₩148,300 ≈ US$106 · Market cap ₩2.7tn (≈ $2.0bn)

Home › 310210 › Filings

Material matter affecting investment judgment

DART

Voronoi, Inc.

Filed Sep 9, 2026 KST · Filing · receipt 20260909900586

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.

Korean form name: 투자판단관련주요경영사항(임상시험계획자진취하등) (VRN110755의 제 1/2상 임상시험)

310210

Price: ₩148,300
Change: -0.94%
Market cap: ₩2.7tn
Prev. close: ₩149,700

310210 Summary Compare to Peers

310210 data on kstock

Financials: 11 fiscal years
Valuation: Daily P/E, P/S, P/B, P/CF
Earnings: Eight quarters
Dividends: Per-share history

Every figure is taken from Voronoi, Inc.'s own DART filings and matched on IFRS account codes, so a line holds across years where the Korean wording changed.

More 310210 filings

Grant of stock options

09/09/26

Material matter affecting investment judgment (clinical trial plan amendment applied for)